Associated Genetic Biomarkers

Overview

NCI Definition: A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. (WHO 2008) [1]

Myeloproliferative neoplasms most frequently harbor alterations in JAK2, ASXL1, ETV6, TET2, and CDKN2A [2].

Most Commonly Altered Genes in Myeloproliferative Neoplasm

JAK2 Mutation, JAK2 V617F, ASXL1 Mutation, ETV6 Mutation, and ETV6 Frameshift are the most common alterations in myeloproliferative neoplasm [2].

Top Alterations in Myeloproliferative Neoplasm

Significant Genes in Myeloproliferative Neoplasm

ABL1 +

AFF1 +

BCR +

CBFB +

DEK +

ELL +

FGF1 +

FGF10 +

FGF11 +

FGF12 +

FGF13 +

FGF14 +

FGF16 +

FGF17 +

FGF18 +

FGF19 +

FGF2 +

FGF20 +

FGF21 +

FGF22 +

FGF23 +

FGF3 +

FGF4 +

FGF5 +

FGF6 +

FGF7 +

FGF8 +

FGF9 +

FGFR1 +

FGFR2 +

FGFR3 +

FGFR4 +

FLT3 +

IDH1 +

IKZF1 +

KIT +

KMT2A +

MECOM +

MLF1 +

MLLT1 +

MLLT10 +

MLLT3 +

MLLT4 +

MYH11 +

NPM1 +

NUP214 +

PBX1 +

PML +

RARA +

RPN1 +

RUNX1 +

RUNX1T1 +

TCF3 +

TP53 +

Disease Details

Synonyms
MPD, Myeloproliferative Disorder, Chronic Myeloproliferative Disease, Myeloproliferative Tumor, Chronic Myeloproliferative Disorder, Chronic Myeloproliferative Neoplasm, MPN, CMPD
Parent(s)
Myeloid Neoplasm
Children
Primary Myelofibrosis, Chronic Neutrophilic Leukemia, Myeloproliferative Neoplasm, Unclassifiable, Essential Thrombocythemia, Chronic Eosinophilic Leukemia, NOS, Chronic Myeloid Leukemia, and Polycythemia Vera
OncoTree Name
Myeloproliferative Neoplasm
OncoTree Code
MPN

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.